Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



A Phase Ib / II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma

Lymphoma

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (M-CHOP) and, subsequently, in combination with cyclophosphamide, doxorubicin, and prednisone (CHP) plus polatuzumab vedotin (CHP-pola) in participants with relapsed or refractory (R / R) B-cell non-Hodgkin lymphoma (NHL), and in previously untreated participants with diffuse large B-cell lymphoma (DLBCL).
Lymphoma
I/II
Reddy, Nishitha
NCT03677141
VICCPCL18140

Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

Prostate

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.
Prostate
III
Moses, Kelvin
NCT03395197
VICCURO17115

Natalizumab and Prednisone or Methylprednisolone in Treating Participants with High Risk Acute Graft-Versus-Host Disease

Miscellaneous

This phase II trial studies how well natalizumab and prednisone or methylprednisolone work in treating participants with high risk acute graft-versus-host disease. Graft-versus-host disease is caused when cells from a donated stem cell graft attack the normal tissue of the transplant patient. Immunotherapy with monoclonal antibodies, such as natalizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Prednisone and methylprednisolone are steroids that helps suppress the immune system and reduce inflammation. It is not yet known how well natalizumab and prednisone or methylprednisolone work in treating participants with high risk acute graft-versus-host disease.
Miscellaneous
II
Kitko, Carrie
NCT02133924
VICCPED1666

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: